A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2017-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

NCT03495323

Cancer

COMPLETED PHASE1

A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

NCT02778126

Advanced Cancer

COMPLETED PHASE1

A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors

NCT01341457

Solid Tumors

COMPLETED PHASE1

A Study of LY3007113 in Participants With Advanced Cancer

NCT01463631

Metastatic Cancer

COMPLETED PHASE1

A Study of LY2875358 in Japanese Participants With Advanced Cancer

NCT01602289

Solid Tumors Lymphoma Carcinoma, Non-Small-Cell Lung

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prexasertib

Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.

Group Type EXPERIMENTAL

Prexasertib

Intervention Type DRUG

Administered IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prexasertib

Administered IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY2606368

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed
* Participant must have diagnosis of cancer that is advanced or metastatic
* Participant must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy
* If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug
* If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding

Exclusion Criteria

* Participant must not have symptomatic central nervous system malignancy or metastasis
* Participant must not have current hematologic malignancy
* Participant must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
* Participant must not have a serious cardiac condition

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No